Effects of Metformin in a Non-Diabetic Patient Population

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

January 22, 2019

Primary Completion Date

March 31, 2020

Study Completion Date

March 31, 2020

Conditions
Inflammatory Response
Interventions
DRUG

MetFORMIN Hydrochloride ER

Subjects will be exposed to 500mg, 1000mg, or 1500mg of daily ER Metformin, by mouth, for up to 90 days. Subjects will have their venous blood sampled and baseline, throughout the trial, and following completion of their metformin exposure.

DRUG

Placebo

Subjects will be exposed to placebo, by mouth, for up to 90 days. Subjects will have their venous blood sampled and baseline, throughout the trial, and following completion of their metformin exposure.

Trial Locations (1)

15209

University of Pittsburgh Medical Center, Pittsburgh

All Listed Sponsors
lead

Brian Zuckerbraun

OTHER

NCT03772964 - Effects of Metformin in a Non-Diabetic Patient Population | Biotech Hunter | Biotech Hunter